EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis

Andrew M Brown, Ihab Kassab, Marco Massani, Whitney Townsend, Amit G Singal iD, Cigdem Soydal, Laura Moreno-Luna, Lewis R Roberts, Vincent L Chen, Neehar D Parikh iD

Cancer Medicine · 2023-02 · 12 (3) · 2590-2599

DOI: 10.1002/cam4.5125 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Medicine, online erschienen am 09.08.2022. Verfasst von Andrew M Brown und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIMHD NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transarterial radioembolization (TARE) is increasingly used as an alternative to transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). We aimed to perform an overall and individual patient data (IPD) meta‐analysis of studies comparing TACE and TARE.

Methods

We performed a systematic literature search using pre‐specified keywords with the aid of an informationist for articles from inception to 3/2020. The primary endpoint was overall survival (OS), and the secondary endpoint was time to progression (TTP).

Results

Seventeen studies met inclusion criteria with 2465 unique patients, with one randomized trial, 4 prospective studies and 12 retrospective studies. Barcelona Clinic Liver Cancer (BCLC) stage B (42.8%) was the most common stage followed by BCLC A (30.3%) and BCLC C (29.0%). There was no difference in OS between the two modalities (−0.55 months, 95% CI −1.95 to 3.05). In three studies with available TTP data, TARE resulted in a longer TTP than TACE (mean TTP 17.5 vs. 9.8 months; mean TTP difference 4.8 months, 95% CI 1.3–8.3 months). IPD‐level meta‐analysis of 311 patients from three studies showed no difference in overall OS between the two modalities including among subgroups stratified by tumor stage and liver function. Limitations of the current literature include inconsistent length of follow‐up, inconsistency in response criteria, and safety reporting.

Conclusions

Current data suggest TARE provides significantly longer TTP than TACE, although the two treatments do not significantly differ in terms of OS. Given limitations of the current data, there is rationale for prospective studies comparing these modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsHumansProspective StudiesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

HCCTACEY-90locoregional therapy

Autor:innen und Institutionen

  • Division of Gastroenterology and University of Michigan, Ann Arbor, Michigan, USA.
  • Ospedale Regionale Treviso, Treviso, Italy.
  • Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, Texas, USA.
  • Department of Nuclear Medicine, Ankara University Medical School, Ankara, Turkey.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Amit G Singal, Neehar D Parikh

Förderung

  • NIH HHS
  • NIMHD NIH HHS
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Brown, A. M., Kassab, I., Massani, M., Townsend, W., Singal, A. G., Soydal, C., Moreno-Luna, L., Roberts, L. R., Chen, V. L., & Parikh, N. D. (2023). TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Medicine, 12(3), 2590-2599. https://doi.org/10.1002/cam4.5125

Vancouver

Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Medicine. 2023;12(3):2590-2599. doi:10.1002/cam4.5125

BibTeX
@article{Brown2023,
  author = {Brown, Andrew M and Kassab, Ihab and Massani, Marco and Townsend, Whitney and Singal, Amit G and Soydal, Cigdem and Moreno-Luna, Laura and Roberts, Lewis R and Chen, Vincent L and Parikh, Neehar D},
  title = {TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {2590--2599},
  doi = {10.1002/cam4.5125}
}
Kostenlos starten →